Danaher Co. (NYSE:DHR) CEO Sells $11,756,953.50 in Stock

Danaher Co. (NYSE:DHR) CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Danaher Trading Down 1.8 %

Shares of Danaher stock opened at $245.82 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The firm has a market cap of $182.04 billion, a price-to-earnings ratio of 41.66, a price-to-earnings-growth ratio of 4.24 and a beta of 0.83. The business has a fifty day simple moving average of $248.94 and a 200-day simple moving average of $230.88. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.48% and a net margin of 16.78%. The company’s revenue was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.36 earnings per share. On average, equities analysts forecast that Danaher Co. will post 7.62 EPS for the current fiscal year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a $0.27 dividend. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio is 18.31%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. TD Cowen upped their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday. Robert W. Baird upped their price objective on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and upped their price objective for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, KeyCorp upped their price objective on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Six analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $270.00.

Institutional Trading of Danaher

Several institutional investors have recently modified their holdings of DHR. Tsfg LLC raised its position in shares of Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the period. Cape Investment Advisory Inc. acquired a new stake in shares of Danaher during the fourth quarter worth $25,000. BKM Wealth Management LLC acquired a new stake in shares of Danaher during the fourth quarter worth $27,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher during the first quarter worth $30,000. Finally, Wetzel Investment Advisors Inc. acquired a new stake in shares of Danaher during the fourth quarter worth $29,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.